Cyclica, founded in 2013, is a pioneering company in the Biotechnology, Health Care, and Pharmaceutical industries. With the slogan, "Discovering Drug through Proteome Docking to advance molecules that embrace the complexity of the disease," the company utilizes AI-enhanced drug discovery methods to revolutionize the identification and development of new drugs. By leveraging cutting-edge machine learning techniques, Cyclica aims to address the intricate complexities inherent in diseases, striving to shift the traditional drug discovery approach.
The company caters to a wide variety of clients, including pharmaceutical companies, biotech firms, and academic institutions. Its innovative approach caught the attention of Recursion Pharma, which invested $40.00M in an acquisition investment dated 01 May 2023. This backing underscores Cyclica's potential to make a significant impact on the future of drug discovery and development.
